These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 954793)

  • 41. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aspects of treatment of more advanced cases of ovarian cancer.
    Hudson CN; Dendy PP
    Proc R Soc Med; 1974 Aug; 67(8):798-801. PubMed ID: 4418734
    [No Abstract]   [Full Text] [Related]  

  • 43. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
    Chylak V; Kolarić K; Krusić J
    Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515
    [No Abstract]   [Full Text] [Related]  

  • 44. [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
    Teufel G; Pfleiderer A
    Geburtshilfe Frauenheilkd; 1976 Mar; 36(3):274-9. PubMed ID: 1261795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of iatrogenic leukopenia and thrombopenia in bronchial carcinoma using a blood extract].
    Baldamus U; Rahlfs V; Steffen J
    Blut; 1970; 20(6):350-62. PubMed ID: 4912589
    [No Abstract]   [Full Text] [Related]  

  • 46. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second-line efficacy of intermediate high-dose methotrexate with citrovorum factor rescue + cyclophosphamide in ovarian cancer.
    Barlow JJ; Piver MS
    Gynecol Oncol; 1979 Apr; 7(2):233-8. PubMed ID: 312234
    [No Abstract]   [Full Text] [Related]  

  • 48. [Chemotherapy in the treatment of cases of advanced ovarian cancer].
    Jentys W; Piatkowski Z
    Ginekol Pol; 1974 Nov; 45(11):1285-91. PubMed ID: 4430455
    [No Abstract]   [Full Text] [Related]  

  • 49. Modeling toxicity and response in carboplatin-based combination chemotherapy.
    Egorin MJ; Reyno LM; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):7-19. PubMed ID: 7992070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
    Ehninger G; Weible KH; Heidemann EG; Waller HD
    Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
    Ringborg U; Lewensohn R
    Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple myeloma--intermittent combination chemotherapy compared to continuous therapy.
    George RP; Poth JL; Gordon D; Schrier SL
    Cancer; 1972 Jun; 29(6):1665-70. PubMed ID: 4113171
    [No Abstract]   [Full Text] [Related]  

  • 54. [Experience with clinical use of cyclophosphane].
    Raevskiĭ IG
    Klin Med (Mosk); 1966 Jan; 44(1):98-103. PubMed ID: 4293574
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cyclophosphamide as adjuvant treatment of the advanced ovarian carcinoma].
    Malkasian GD; Mussey E; Decker DG; Johnson CE
    Gynecol Prat; 1967; 18(6):545-53. PubMed ID: 4316435
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comprehensive therapy of ovarian neoplasms. 3. Our results of chemotherapy in progressive ovarian neoplasms].
    Dvorák O
    Zentralbl Gynakol; 1972 Mar; 94(10):330-2. PubMed ID: 4113133
    [No Abstract]   [Full Text] [Related]  

  • 58. cis-Dichlorodiammineplatinum(II) and adriamycin treatment of advanced ovarian cancer.
    Briscoe KE; Pasmantier MW; Ohnuma T; Kennedy BJ
    Cancer Treat Rep; 1978 Dec; 62(12):2027-30. PubMed ID: 751711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II evaluation of mitozolomide in ovarian cancer.
    Harding M; Northcott D; Smyth J; Stuart NS; Green JA; Newlands E
    Br J Cancer; 1988 Jan; 57(1):113-4. PubMed ID: 3348943
    [No Abstract]   [Full Text] [Related]  

  • 60. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.